Experimental heart slicing procedure tested on one patient

NCT ID NCT06269640

Terminated Disease control Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tested a new procedure called SESAME that uses a wire threaded through blood vessels to slice away excess heart muscle in people with hypertrophic cardiomyopathy. Only one adult participated before the study was terminated. The goal was to see if the technique could safely reduce blockage of blood flow from the heart.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Septal Scoring Along Midline Endocardium (SESAME) device
What this could lead to: If refined, this could offer a less invasive alternative to open-heart surgery for reducing thickened heart muscle and improving blood flow.
What could go wrong: This was a very early feasibility study with only 1 participant and was terminated. The procedure carries serious risks like stroke, heart damage, or need for a pacemaker.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis hypertrophic cardiomyopathy mitral valve disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTIC VALVE STENOSIS HYPERTROPHIC CARDIOMYOPATHY LEFT VENTRICULAR SEPTAL HYPERTROPHY MITRAL VALVE DISEASE

Experimental heart slicing procedure tested on one patient

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions